How to Evaluate a Pharmaceutical Temperature Excursion Using Stability Data and Risk-Based Logic

Why stability data has to be at the center of the assessment

ICH Q1A (R2) frames stability testing as the evidence used to show how the quality of a drug substance or drug product changes over time under the influence of environmental factors such as temperature and storage conditions.^[1] That point is foundational. Excursion review is not a separate scientific universe. It is an application of the same stability logic used to support shelf life and storage labeling.

When an excursion occurs, the first question is not whether the chart "looks bad." The first question is whether the observed thermal exposure, in the context of the specific product, could plausibly alter quality-relevant characteristics. That requires reference to approved storage conditions, available stability data, dosage-form sensitivity, packaging protection, and any relevant known degradation behavior. A sterile biologic, a small-molecule tablet, and a topical semisolid may all respond very differently to the same apparent temperature event.

The EU GDP guideline strengthens this approach by requiring defined storage conditions during transport and by expecting organizations to be able to demonstrate that products were not exposed to conditions that compromise quality and integrity.^[2] A scientifically credible excursion workflow therefore has to connect transport evidence, product knowledge, and written rationale.

A practical end-to-end workflow for evaluating an excursion

A reliable review process starts with event confirmation. Teams should confirm that the excursion is real, not an artifact caused by device malfunction, data corruption, or improper logger placement. That means reviewing calibration status, timestamp integrity, unit settings, and whether the recorded location is representative of product exposure. If the underlying data is unreliable, the downstream conclusion will be weak regardless of how polished the report looks.

Once the event is confirmed, the next step is to define the actual excursion window. This includes the start time, end time, highest and lowest readings, and the shape of the exposure profile. The relevant period should reflect the product’s actual experience, not an arbitrary historical average. Where helpful, supporting calculations such as mean kinetic temperature may be added, but they should remain secondary to the event itself.^[1]

The third step is to confirm the applicable storage requirement for the exact product presentation and batch context. The assessment must use the approved condition that truly applies. Errors often arise when teams rely on generic warehouse rules instead of the product’s authorized labeling, registration file, or internal quality basis.

The fourth step is to review the stability evidence. This may include long-term data, intermediate data, accelerated studies, stress or forced degradation information, and any known sensitivity of critical quality attributes. The goal is not to cite every available data set, but to identify what is relevant to the temperature range and duration actually observed. This is where risk-based logic becomes more than a slogan. A ten-minute exposure to a modest overage and a multi-hour event well beyond label limits do not carry the same interpretive burden.

The fifth step is to assess magnitude, duration, and direction together. Some products are more vulnerable to freezing than to heat. Others may tolerate a limited high-side event but not repeated exposures. The magnitude of the deviation, the time spent outside limit, and the presence of repeated or cumulative events should all be considered in combination rather than one at a time.

The sixth step is to evaluate product-specific modifiers. These include dosage form, primary packaging, route profile, validated shipping configuration, and any prior deviations already logged against the batch or comparable product. A risk-based assessment that ignores packaging or cumulative exposure is often incomplete.

The seventh step is to convert the technical review into a documented conclusion. The written rationale should explain the event, identify the evidence reviewed, state the reasoning, and make clear why the final disposition is supportable. If the evidence is insufficient, the correct conclusion may be escalation, quarantine, additional testing, or rejection rather than premature acceptance.

How risk-based logic should be applied

Risk-based logic does not mean "be flexible." It means the depth of the assessment should be proportionate to the quality risk presented by the event. EU GDP explicitly refers to the use of a risk-based approach in transportation planning, and the same mindset is appropriate when evaluating deviations after the fact.^[2]

In practice, a stronger risk signal may come from several sources: exposure far outside approved limits, a long duration, a sensitive product class, a known instability mechanism, weak packaging protection, repeat excursions, or uncertainty in the logger evidence. When several of those factors are present at the same time, the assessment should become more conservative and more evidence-intensive.

The reverse is also true. If the event is brief, the temperature overage is limited, the logger record is strong, the product has supportive stability knowledge, and the packaging configuration is well understood, a well-documented low-risk conclusion may be possible. The point is not to force every case into the same outcome. The point is to make the logic explicit and traceable.

Common mistakes that weaken excursion investigations

One frequent mistake is evaluating the event against a generic distribution policy rather than the specific product’s approved storage basis. Another is focusing on the maximum temperature only, without considering duration, excursion profile, or cumulative exposure. A third is over-relying on a summary metric such as MKT without linking it back to product-specific stability data.^[4]

Documentation failures are equally common. EU GDP states that if a deviation such as a temperature excursion occurs during transportation, it should be reported to the distributor and recipient, and a procedure should be in place for investigating and handling temperature excursions.^[2] If the organization cannot show a consistent written process, even a technically reasonable conclusion may appear weak during audit or inspection.

From the QP side, Annex 16 is especially relevant because it states that the QP must ensure each batch has been manufactured and checked in compliance with the marketing authorisation and GMP, and that storage and transport conditions for the batch and sample should be taken into account before certification.^[3] That means excursion assessments feed directly into release confidence, not just logistics reporting.

How ExcursionAssess can support the workflow

ExcursionAssess can add value when it helps teams move from fragmented records to a structured review path. The platform should be seen as a way to organize evidence, standardize the sequence of assessment steps, and improve the quality of the written rationale. That kind of support is especially useful when different stakeholders, such as supply chain, QA, technical services, and QP reviewers, need to work from the same event record.

A strong decision-support workflow can help teams capture logger data, define the excursion window, connect the event to approved product context, and document what evidence was reviewed. It can also support consistency in how cases are escalated and how final conclusions are recorded. What it should not do is imply that batch disposition can be automated without scientifically grounded human oversight.

Conclusion

A sound pharmaceutical excursion assessment is neither a purely operational exercise nor a purely mathematical one. It is a structured stability-informed quality decision. The best reviews begin with verified event data, stay anchored to approved storage conditions, use stability evidence intelligently, and document the logic clearly enough that another competent reviewer can understand and defend the conclusion.^{[1] [3]}

If your organization wants a more consistent and auditable process for these cases, ExcursionAssess can help structure the assessment workflow, centralize the evidence, and improve the quality of the written rationale that supports QA and QP review.